17:40 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Mouse studies suggest combined promotion of BDNF expression and neurogenesis could help treat AD. In a mouse model of familial AD, the combination of three agents -- a tool compound that...
15:21 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample and cell culture studies suggest inhibiting BDNF-TrkB signaling could help treat prostate cancer in African-American patients. In prostate fibroblasts isolated from four African-American patients, levels of BDNF were higher than...
22:10 , Sep 6, 2018 |  BC Extra  |  Preclinical News

Dual therapy could treat AD -- if it can cross into clinic

Researchers at Massachusetts General Hospital and colleagues found concurrently inducing neurogenesis and raising neuroprotective brain-derived neurotrophic factor (BDNF) levels could treat Alzheimer's disease, but it's not clear if -- or how -- such strategies could...
17:25 , Aug 17, 2018 |  BC Week In Review  |  Company News

Astellas acquires ophthalmic company Quethera

Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85 million ($110.3 million). "This acquisition is a strategic fit as Astellas has prioritized ophthalmology as a new focus...
16:06 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest a TrkB-agonizing BDNF peptide could help treat demyelination diseases. In a mouse model of CNS demyelination, intracerebroventricular infusion of a previously reported tricyclic BDNF peptide agonist of TrkB (EC 50...
21:27 , Aug 10, 2018 |  BC Extra  |  Company News

Astellas acquires ophthalmic company Quethera

Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85 million ($110.3 million). "This acquisition is a strategic fit as Astellas has prioritized ophthalmology as a new focus...
20:45 , Sep 14, 2017 |  BC Innovations  |  Translation in Brief

Tracking TrkB agonists

It turns out that neurotrophic TrkB agonists used in many publications aren't TrkB agonists after all, according to a recent...
16:22 , Aug 31, 2017 |  BC Innovations  |  Translation in Brief

Extinguishing aversion

Last month in the...
14:18 , Dec 22, 2016 |  BC Innovations  |  Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: RAB3A member RAS oncogene family (RAB3A); brain-derived neurotrophic factor (BDNF)

Neurology INDICATION: Huntington's disease (HD) Mouse studies suggest promoting astrocyte RAB3A expression could help treat HD. In a mouse model of HD, transgenic expression of mouse RAB3A in striatal astrocytes increased BDNF secretion and decreased...